Key result
Continuing antithrombotics during head and neck surgery shows no difference in bleeding versus discontinuation.
Why the study?
Perioperative management of antithrombotic agents may affect bleeding and thromboembolic complications, but there is no consensus on the optimal protocol in head and neck surgery.
Does continuing antithrombotic therapy increase intraoperative blood loss or postoperative bleeding in patients undergoing surgery for head and neck malignancies?
Observational (n=168)
Does continuing antithrombotic therapy increase intraoperative blood loss or postoperative bleeding in patients undergoing surgery for head and neck malignancies?
Continuing antiplatelet therapy during surgery for head and neck malignancies does not appear to increase bleeding complications, suggesting it may be safely maintained.
May support continuing antithrombotic therapy without excess bleeding in head and neck cancer surgery; leaves open need for randomized confirmation.
Introduction Perioperative management of antithrombotic agents may affect bleeding and lead to thromboembolic complications, but there is no consensus on optimal protocol in head and neck surgery. Objective To explore the effect of antithrombotic agents on postoperative bleeding. Methods We compared clinical characteristics, type of surgery, antithrombotic agents, continued use of medication or not, and frequency of postoperative bleeding among patients who were receiving antithrombotic therapy at the time of their decision to undergo surgery for head and neck malignancies, from 2008 to 2022. Results A total of 168 patients were included. There was no significant difference in the incidence of intraoperative blood loss or postoperative bleeding between the group that underwent surgery while on antithrombotic therapy and those that underwent surgery after antithrombotic therapy was discontinued. In particular, there was no increase in bleeding complications with antiplatelet agents, regardless of the type or number of agents used. Conclusion Surgery for head and neck malignancies with continued antiplatelet therapy may not increase bleeding complications, regardless of the type of antiplatelet therapy and even when multiple agents are taken.
No takes yet. Share an insight, caveat, or question.
Ushiro et al. (2025) conducted an observational in Head and neck malignancies (n=168). Continued antithrombotic therapy vs. Discontinued antithrombotic therapy was evaluated on Intraoperative blood loss or postoperative bleeding. Continuing antithrombotic therapy during surgery for head and neck malignancies showed no significant difference in intraoperative blood loss or postoperative bleeding compared to discontinuation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: